Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China.
Department of Hematology, Wuxi People's Hospital Affiliated to Nanjing Medical University, WuXi, China.
Cancer Med. 2024 Mar;13(5):e7062. doi: 10.1002/cam4.7062.
Blinatumomab early-line treatment in B-cell precursor acute lymphoblastic leukemia (B-ALL) might improve clinical outcomes.
We conducted a retrospective real-world cohort analysis in 20 newly diagnosed B-ALL patients who received reduced-dose chemotherapy (idarubicin, vindesine, and dexamethasone) for 1-3 weeks, followed by blinatumomab for 1-4 weeks as an induction therapy.
At the end of the induction therapy, a complete remission rate of 100% was achieved; 17 (85%) patients were minimal residual disease (MRD) negative (<1 × 10 ). Adverse events (AEs) were reported in 12 (60%) patients-43.8% were grade 1-2 and 56.2% were grade 3-4. No incidence of neurotoxicity or grade ≥3 cytokine release syndrome was reported.
Blinatumomab demonstrated a significant improvement in clinical outcomes in patients with newly diagnosed B-ALL irrespective of their poor-risk factor status and the pretreatment blast burden.
Blinatumomab 在 B 细胞前体急性淋巴细胞白血病 (B-ALL) 中的早期治疗可能改善临床结局。
我们对 20 例新诊断的 B-ALL 患者进行了回顾性真实世界队列分析，这些患者接受了 1-3 周的低剂量化疗（伊达比星、长春碱和地塞米松），随后接受 Blinatumomab 治疗 1-4 周作为诱导治疗。
在诱导治疗结束时，完全缓解率达到 100%；17 例（85%）患者微小残留病（MRD）阴性（<1×10 ）。12 例（60%）患者发生不良反应（AE）-43.8%为 1-2 级，56.2%为 3-4 级。未报告神经毒性或≥3 级细胞因子释放综合征的发生率。
Blinatumomab 使新诊断的 B-ALL 患者的临床结局显著改善，无论其是否存在不良风险因素和预处理 blast 负担。
